OGOlivier Gaubert

Olivier Gaubert

*This is an algorithmically generated author record based on publicly available information.

Olivier Gaubert has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Positive Airway Pressure-Related Aerophagia in Obstructive Sleep Apnea: Results from the InterfaceVent Real-Life Study

    by Celia Vidal, Jean-Pierre Mallet, Sarah Skinner, Raphael Gilson, Olivier Gaubert, Arnaud Prigent, Frédéric Gagnadoux, Jean-Christian Borel, Arnaud Bourdin, Nicolas Molinari, et al.

    Background: Continuous positive airway pressure (CPAP) effectiveness can be compromised by adverse effects. Despite its potential impact on adherence and sleepiness, aerophagia remains under-recognized and poorly characterized. This ancillary analysis of the InterfaceVent study aimed to identify risk factors for aerophagia in a large real-life cohort of CPAP-treated patients and to assess its association with both CPAP adherence and sleepiness. Methods: InterfaceVent was a prospective, real-life, cross-sectional study. Adults treated for at least 3 months with CPAP were included. Patients self-reported mask-related side effects using visual analogue scales. Aerophagia was defined as a dichotomous outcome based on patient-reported symptoms and CPAP non-adherence as mean nightly usage p < 0.001). CPAP usage was significantly lower in the aerophagia group (median 6.37 vs. 6.75 h/day; p = 0.001), whereas non-adherence, did not significantly differ between groups (10.7% vs. 7.5%; p = 0.20). Conclusions: This ancillary analysis of the InterfaceVent study highlights the burden of aerophagia in CPAP-treated patients and identifies modifiable and non-modifiable risk factors. Better recognition and management of this under-reported side effect may improve CPAP adherence and patient comfort. Trial registration: InterfaceVent is registered with ClinicalTrials.gov (NCT03013283). The first registration date is 23 December 2016.


  • Open Access

    Concerns arising from the calculation of the apnea-hypopnea index during CPAP-telemonitoring of patients with obstructive sleep apnea

    by Celia Vidal, Jean-Pierre Mallet, Sarah Skinner, Raphael Gilson, Olivier Gaubert, Arnaud Prigent, Frédéric Gagnadoux, Arnaud Bourdin, Nicolas Molinari, Dany Jaffuel

    Continuous Positive Airway Pressure (CPAP) telemonitoring is increasingly important in managing obstructive sleep apnea (OSA). The Apnea-Hypopnea Index reported by CPAP devices (AHIflow) is used as a key indicator of treatment effectiveness. However, discrepancies in AHIflow calculation rules between manufacturers may affect clinical decision-making. No prior studies have investigated whether manufacturers’ choices to exclude certain apnea-hypopnea events from the AHIflow calculation may influence the number of patients presenting an AHIflow alert. The aim of this proof-of-concept study was not to compare the manufacturers with each other, but to evaluate, for each manufacturer, how the different possible ways of calculating AHIflow influence the percentage of alert cases. We conducted a retrospective analysis of 13,764 CPAP-treated OSA patients monitored on October 2, 2023. AHIflow calculations were evaluated according to manufacturer-specific rules. When possible, we assessed the impact of excluding central hypopneas, events during major leaks, and/or ramp periods on the percentage of patients crossing the consensual AHIflow alert threshold of ≥ 10 events/h. We identified significant disparities in AHIflow calculations between manufacturers, which lead to significant differences in the number of patients flagged as being in an alert state. Excluding central hypopneas reduced the number of alert cases by 50%, while excluding apneas/hypopneas during major leaks or ramp periods reduced alerts by 20%. Our proof-of-concept study highlights inconsistencies in AHIflow calculations among CPAP manufacturers, raising concerns about patient care. Establishing standardized AHIflow calculation criteria is essential to ensuring accurate monitoring and optimal patient safety.


  • The influence of atmospheric temperature on long-term CPAP-usage in patients with obstructive sleep apnea

    by Celia Vidal, Jean-Pierre Mallet, Sarah Skinner, Raphael Gilson, Olivier Gaubert, Arnaud Prigent, Frédéric Gagnadoux, Arnaud Bourdin, Nicolas Molinari, Dany Jaffuel


  • Open Access

    Did COVID-19 impact Positive Airway Pressure adherence in 2020? A cross-sectional study of 8477 patients with sleep apnea

    by Fanny Bertelli, Carey M. Suehs, Jean-Pierre Mallet, Isabelle Court-Fortune, Frédéric Gagnadoux, Jean Christian Borel, Olivier Gaubert, Nicolas Molinari, Arnaud Bourdin, Dany Jaffuel

    Background: Whether the COVID-19 pandemic impacts Positive Airway Pressure (PAP) adherence over the long-term is unknown and only preliminary short-term data have been reported. Methods: With the aim of describing the impact of the first and second waves of COVID-19 on PAP adherence during 2020 in France, we designed a cross-sectional study of Sleep-Apnea (SA)-patients under PAP telemonitoring. To examine PAP adherence in adult SA patients, we assessed de-identified data from a non-profit healthcare provider database during the period January 1, 2019 to December 31, 2020. Included patients met the following criteria: (i) PAP-treated for at least 4 months before January 1, 2019 and with continuous PAP during both 2019 and 2020; (ii) ≥ 360 daily PAP telemonitored data per year. For PAP adherence, data were collected using the PAP-software. Results: 8477/10482 patients were finally included in the analysis [72.4% male, median age 70 years (IQ25–75: 61–77], 25.6% < 62 years old, initial Apnea–Hypopnea Index (AHI) of 41 (31–59)/h. Median PAP adherence was 7.21 (6.12–8.10) h/day in 2020 versus 7.12 (6.05–8.02) h/day in 2019, p < 0.001. The median difference in PAP adherence between the first 2020 lockdown and the corresponding 2019 weeks was 9.75 (CI95% 8.75–10.75) min/day, p < 0.001. The median difference in PAP adherence between the second 2020 lockdown and the corresponding 2019 weeks was 5.00 (CI95% 4.00–6.00) min/day, p < 0.001. If we consider the minimal clinically important difference of 30 min for PAP adherence, 30.4% and 26% of the patients increased their PAP adherence by at least 30 min during the first and second lockdowns respectively; 17.6% and 19.3% of the patients lowered their PAP adherence by at least 30 min in the first and second lockdowns, respectively. Conclusion: During the first and second lockdowns, the COVID-19 pandemic had a clinically irrelevant effect on PAP adherence for the study population. Future studies are needed to describe COVID-19 pandemic impact on PAP adherence not only for long-term PAP-treated SA patients but also for incident cases. Trial registration The COVADENE study was registered on March 1st, 2021 on ClinicalTrials.gov (Identifier: NCT04775966)